: Biogen prices new ALS treatment at $14,230 per vial


Biogen Inc. BIIB has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also known as tofersen, was granted accelerated approval by the U.S. Food and Drug Administration last week. The treatment is administered through a spinal injection. The price tag of $14,230 is the wholesale acquisition cost, the spokesperson said. Biogen stock was down 1.2% Tuesday, but has gained 11% in the year to date, while the S&P 500 has gained 8.6%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleBond Report: Treasury yields turn lower after data on U.S. factory orders and job openings
Next articleShort seller Hindenburg sets sights on Icahn Enterprises, driving the stock down


Please enter your comment!
Please enter your name here